CTR9 (TSBP) as a Drug Target and Biomarker: Implications for Cancer Treatment

Target Name: CTR9

NCBI ID: G9646

CTR9

CTR9 (TSBP) as a Drug Target and Biomarker: Implications for Cancer Treatment

Abstract:

CTR9 (Tumor suppressor gene 9), also known as TSBP, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for cancer treatment. CTR9 is expressed in most tissues and has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation. Several studies have investigated the potential clinical applications of CTR9 as a drug target and biomarker, including its potential as a anti-cancer agent, neuroprotectant, and potential target for personalized medicine. This review article will discuss the current state of research on CTR9, its potential implications as a drug target and biomarker, and future directions for research in this field.

Introduction:

CTR9 (Tumor suppressor gene 9) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for cancer treatment. CTR9 is expressed in most tissues and has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation [1,2]. Several studies have investigated the potential clinical applications of CTR9 as a drug target and biomarker, including its potential as an anti-cancer agent, neuroprotectant, and potential target for personalized medicine.

The Potential Role of CTR9 as a Drug Target:

CTR9 has been shown to play a role in various cellular processes that are associated with cancer development and progression. For example, CTR9 has been shown to promote the growth and survival of cancer cells [3,4]. CTR9 has also been shown to play a role in the regulation of cell apoptosis, which is a critical mechanism that helps maintain tissue homeostasis and eliminate damaged or dysfunctional cells [5,6].

In addition to its role in cell growth and apoptosis, CTR9 has also been shown to play a role in inflammation. CTR9 has been shown to regulate the production and function of immune cells, which play a critical role in fighting off cancer [7,8].

The Potential Role of CTR9 as a Biomarker:

CTR9 has also been shown to be a potential biomarker for cancer diagnosis and treatment. CTR9 has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer [9,10]. CTR9 has also been shown to be a potential target for cancer immunotherapy, which involves the use of antibodies to target and destroy cancer cells [11,12].

In addition to its potential as a drug target, CTR9 has also been shown to have potential as a biomarker for cancer diagnosis and treatment. CTR9 has been shown to be a potential biomarker for breast cancer, with studies showing that higher levels of CTR9 are associated with a more aggressive form of breast cancer [13,14]. CTR9 has also been shown to be a potential biomarker for lung cancer, with studies showing that higher levels of CTR9 are associated with a more aggressive form of lung cancer [15,16].

Future Directions for Research:

Several future directions for research on CTR9 include further investigation of its potential as a drug target and biomarker for cancer treatment. For example, researchers may investigate the efficacy of CTR9 as an anti-cancer agent, either alone or in combination with other treatments. Researchers may also continue to investigate the potential role of CTR9 as a biomarker for cancer diagnosis and treatment.

Conclusion:

CTR9 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for cancer treatment. CTR9 is expressed in most tissues and has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation. Several studies have investigated the potential clinical applications of CTR9 as

Protein Name: CTR9 Homolog, Paf1/RNA Polymerase II Complex Component

Functions: Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Required for mono- and trimethylation on histone H3 'Lys-4' (H3K4me3) and dimethylation on histone H3 'Lys-79' (H3K4me3). Required for Hox gene transcription. Required for the trimethylation of histone H3 'Lys-4' (H3K4me3) on genes involved in stem cell pluripotency; this function is synergistic with CXXC1 indicative for an involvement of the SET1 complex. Involved in transcriptional regulation of IL6-responsive genes and in JAK-STAT pathway; may regulate DNA-association of STAT3 (By similarity)

The "CTR9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTR9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets